Forest Laboratories Inc., of New York, and Gedeon Richter Plc, of Budapest, Hungary, reported positive top-line results from a global, randomized, placebo-controlled, fixed-dose, eight-week phase IIb trial evaluating the efficacy and safety of cariprazine in patients with depressive episodes of bipolar I disorder.